Travere Therapeutics Reports $224.6M Revenue in Q3 2026, Misses Estimates; GAAP Loss at $0. ...
FILSPARI Sales Surge 120% Year-over-Year, Yet Bottom Line Slips Below Analyst Expectations Related Stocks: TVTX ,
FILSPARI Sales Surge 120% Year-over-Year, Yet Bottom Line Slips Below Analyst Expectations Related Stocks: TVTX ,